DarioHealth Chosen by Attain Health for Pilot Study to Improve Cystic Fibrosis Related Diabetes Management
CAESAREA, Israel, Aug. 22, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today it has entered into an agreement with Attain Health, a provider of integrative health coaching for individuals living with cystic fibrosis, to pilot the DarioEngage platform for the management of cystic fibrosis related diabetes (CFRD). CFRD is a unique from of diabetes that occurs in a subset of the estimated 30,000 Americans and 70,000 people worldwide living with cystic fibrosis.
The focus of the study will be to partner with clients and their care teams to more efficiently manage hyperglycemia in people living with cystic fibrosis. The goal of this pilot is to reduce the risk of bacterial infections in the lungs, improve the overall prognosis of the individual. Prior published studies have shown a correlation between high blood sugars and lung infections in cystic fibrosis patients. The 3 month pilot program will track 12 patients with CFRD. Real-time, patient-specific data through DarioEngage is expected to help clinics identify blood glucose trends that may lead to accelerated disease progression. DarioHealth's ability to push health education content through the app is expected to further improve disease management. Attain Health has committed to the pilot by paying for access to the DarioEngage Dashboard to help monitor the DarioHealth sponsored patients.
Attain Health and DarioHealth plan to jointly present preliminary findings from the pilot study in at the North American Cystic Fibrosis Conference on October 18-20, 2018 in Denver, Colorado. Final results from the study are expected in December 2018.
"Effective diabetes management in cystic fibrosis patients is critical, as there is a 6-fold increase in mortality amongst cystic fibrosis patients who have diabetes, as compared to those who don't. The increased risk of mortality from lung infections is correlated with hyperglycemic events," stated Kat Quinn Porco, Founder of Attain Health and a Key Opinion Leader in cystic fibrosis patient coaching and care. "We are very excited to move forward with DarioHealth in exploring the benefits of digital health solutions for patients living with cystic fibrosis. We chose to work with DarioHealth because of their platform's patient-centric approach, ease of use, real time actionable data, and their very favorable reputation in the diabetes market."
"While cystic fibrosis is already a complex disease that requires patient coaching and self-care, the added burden of managing diabetes in these patients in order to reduce the chance of lung infection is a clear unmet medical need. Following the 3-month pilot, Attain Health will seek to obtain grant funding for continuous use of the DarioEngage program with up to 200 patients a year," Porco added.
"By piloting this study in partnership with Attain Health, DarioHealth is taking a leadership position in addressing CFRD by deploying what we believe are the best digital health management tools on the market today. This agreement and pilot study mark DarioHealth's foray into chronic disease treatment markets that overlap with and expand beyond the treatment of diabetes, our company's first treatment indication," commented Erez Raphael, President and CEO of DarioHealth.
About Attain Health
Attain Health is an integrative health coaching and physical performance program focused on patient-centered care, engaging individuals living with cystic fibrosis to optimize their health. Attain Health was created to work collaboratively with patients and their care teams to become empowered, activated and to establish a mindset of adherence. Our platform of Integrative Health and Performance Coaching follows the Duke Integrative Health Coaching model to provide a program that will create lasting change in client's lives.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today's day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize self-diabetes management in a totally new way without having the disease slow them down. DarioHealth has a commercial office in New York with an R&D center in Caesarea, Israel. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes new offerings and enhancements to promote the long-term use of its platform, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario(TM)) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact:
Joao Mendes-Roter
VP Marketing
joao@mydario.com
+1-914-775-5548
DarioHealth Investor Relations Contact:
Westwicke Partners
Dario@Westwicke.com
+1-443-213-0500
View original content with multimedia:http://www.prnewswire.com/news-releases/dariohealth-chosen-by-attain-health-for-pilot-study-to-improve-cystic-fibrosis-related-diabetes-management-300700818.html
SOURCE DarioHealth Corp.
